In this randomized controlled trial, lixisenatide reduced motor disability progression in Parkinson’s patients.
2. Individuals in the lixisenatide group experienced greater gastrointestinal side effects rates than individuals in the placebo group.
Evidence Rating Level: 1 (Excellent)
prepare for a dramatically worse progression of diseaseAustralian trial gives new hope for Parkinson’s disease treatment
Diabetic drug could slow the progression of Parkinson’s disease
Cough syrup drug being trialed as Parkinson’s treatmentParkinson’s UK Award Targets New Therapies that slows disease progression
